At this time, there are three published CV safety outcome trials for the GLP-1 receptor agonists: lixisenatide in acute coronary syndrome (ELIXA) trial [53], liraglutide effect and action in diabetes: evaluation of CV outcome results (LEADER) [54], and trial to evaluate CV and other long-term outcomes with semaglutide in subjects with type 2 diabetes (SUSTAIN-6) [55] conducted with lixisenatide, liraglutide, and semaglutide and with a median follow-up of 2.1, 3.8 and 2.0 years, respectively. Here, GLP1R is linked to diabetes mellitus.